[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201491008A1 - Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита - Google Patents

Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита

Info

Publication number
EA201491008A1
EA201491008A1 EA201491008A EA201491008A EA201491008A1 EA 201491008 A1 EA201491008 A1 EA 201491008A1 EA 201491008 A EA201491008 A EA 201491008A EA 201491008 A EA201491008 A EA 201491008A EA 201491008 A1 EA201491008 A1 EA 201491008A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pump inhibitor
crth2
anthagonist
protone
treatment
Prior art date
Application number
EA201491008A
Other languages
English (en)
Other versions
EA026456B1 (ru
Inventor
Марк Энтони Пэйтон
Эрик Рой Петтифер
Original Assignee
Атопикс Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Атопикс Терапьютикс Лимитед filed Critical Атопикс Терапьютикс Лимитед
Publication of EA201491008A1 publication Critical patent/EA201491008A1/ru
Publication of EA026456B1 publication Critical patent/EA026456B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Описаны способы и композиции для предотвращения, лечения или смягчения эозинофильного эзофагита (ЭоЭ) у индивидуума, включающие введение указанному индивидууму терапевтически эффективного количества по меньшей мере одного антагониста CRTH2 или его фармацевтически приемлемой соли и по меньшей мере одного ингибитора протонного насоса (PPI) или его фармацевтически приемлемой соли. Также описаны композиции, содержащие по меньшей мере один антагонист CRTH2 или его фармацевтически приемлемую соль и по меньшей мере один ингибитор протонного насоса или его фармацевтически приемлемую соль.
EA201491008A 2011-12-16 2012-12-14 Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита EA026456B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576640P 2011-12-16 2011-12-16
PCT/GB2012/000904 WO2013088109A1 (en) 2011-12-16 2012-12-14 Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis

Publications (2)

Publication Number Publication Date
EA201491008A1 true EA201491008A1 (ru) 2015-02-27
EA026456B1 EA026456B1 (ru) 2017-04-28

Family

ID=47470031

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491008A EA026456B1 (ru) 2011-12-16 2012-12-14 Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита

Country Status (14)

Country Link
US (1) US20140328861A1 (ru)
EP (1) EP2790696A1 (ru)
JP (1) JP2015500326A (ru)
KR (1) KR20140113667A (ru)
CN (1) CN104114169A (ru)
AU (1) AU2012351342A1 (ru)
BR (1) BR112014014558A8 (ru)
CA (1) CA2859284A1 (ru)
EA (1) EA026456B1 (ru)
IL (1) IL233131A0 (ru)
MX (1) MX2014007239A (ru)
SG (1) SG11201402796SA (ru)
UA (1) UA112667C2 (ru)
WO (1) WO2013088109A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756270C2 (ru) * 2016-07-21 2021-09-29 Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. Производное индола, используемое в качестве ингибитора CRTH2

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
ES2900342T3 (es) 2012-08-21 2022-03-16 Sanofi Biotechnology Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI634900B (zh) * 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
EP4420734A3 (en) 2015-02-13 2024-11-06 Institut National de la Santé et de la Recherche Médicale Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
EP4059570A1 (en) 2016-01-13 2022-09-21 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
TWI777515B (zh) * 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
MX2019002344A (es) 2016-09-01 2019-09-06 Regeneron Pharma Metodos de prevenir o tratar la alergia administrando un antagonista de il-4r.
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
KR102785099B1 (ko) 2017-10-30 2025-03-26 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
CN107936004B (zh) * 2017-11-30 2020-05-05 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类衍生物
CN107987066B (zh) * 2017-11-30 2020-06-26 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚衍生物
CN107954995B (zh) * 2017-11-30 2020-05-05 正大天晴药业集团股份有限公司 具有crth2抑制剂活性的吲哚衍生物
CN107987072B (zh) * 2017-11-30 2020-06-26 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类化合物
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
KR20210010518A (ko) 2018-05-13 2021-01-27 리제너론 파아마슈티컬스, 인크. Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
CN113597328A (zh) 2019-03-21 2021-11-02 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
KR20220042217A (ko) 2019-08-05 2022-04-04 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
SG11202113310UA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2022020464A1 (en) * 2020-07-21 2022-01-27 Ellodi Pharmaceuticals, L.P. Modified release rapidly disintegrating compositions of proton pump inhibitors

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
JP2006508077A (ja) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
AU2003269327A1 (en) 2002-10-21 2004-05-04 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
CN100406007C (zh) 2002-12-20 2008-07-30 安姆根有限公司 哮喘和过敏性炎症调节剂
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
ATE316077T1 (de) 2003-04-25 2006-02-15 Actimis Pharmaceuticals Inc Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2005007094A2 (en) 2003-07-09 2005-01-27 Tularik Inc. Asthma and allergic inflammation modulators
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005040114A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
SI1718649T1 (sl) 2004-01-31 2009-10-31 Actimis Pharmaceuticals Inc Derivati imidazo 1,2-c pirimidinilocetne kisline
BRPI0508579A (pt) 2004-03-11 2007-08-14 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
CA2558509C (en) 2004-03-11 2011-11-22 Actelion Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
AU2005233125A1 (en) 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
EP2336113A1 (en) 2004-05-29 2011-06-22 7TM Pharma A/S CRTH2 Receptor Ligands for Medical Use
EP1758571A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for therapeutic use
US20080119456A1 (en) 2004-05-29 2008-05-22 Trond Ulven Substituted Thiazoleacetic Acid as Crth2 Ligands
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
CN101087784A (zh) 2004-09-21 2007-12-12 阿特西斯公司 显示crth2受体拮抗性的吲哚乙酸及其应用
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
EP1817282B1 (en) 2004-11-23 2011-07-20 AstraZeneca AB Phenoxyacetic acid derivatives useful for treating respiratory diseases
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
JP2008543726A (ja) 2005-02-24 2008-12-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の処置のためのｐｇｄ２受容体アンタゴニスト
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
BRPI0610035A2 (pt) 2005-04-21 2010-05-18 Serono Lab sulfonamidas de pirazina 2,3 substituìdas
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0510585D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
KR101333861B1 (ko) 2005-05-24 2013-11-28 메르크 세로노 에스. 에이. Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
ATE425791T1 (de) * 2005-07-29 2009-04-15 Rottapharm Spa Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten
EP1915372B1 (en) 2005-08-12 2013-11-20 Merck Canada Inc. Indole derivatives as crth2 receptor antagonists
EP1931632A4 (en) 2005-08-18 2011-05-11 Microbia Inc USEFUL INDOOR CONNECTIONS
GB0518494D0 (en) 2005-09-09 2005-10-19 Argenta Discovery Ltd Thiazole compounds
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
NZ566537A (en) 2005-09-30 2010-10-29 Pulmagen Therapeutics Asthma L Quinolines and their therapeutic use
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
WO2007052023A2 (en) 2005-11-05 2007-05-10 Astrazeneca Ab Novel compounds
WO2007062678A1 (en) 2005-11-29 2007-06-07 7Tm Pharma A/S Phenoxyacetic acid derivatives as crth2 receptor ligands
WO2007062677A1 (en) 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
GB0524427D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Use of receptor ligands in threapy
WO2007068894A2 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
GB0611781D0 (en) 2006-06-14 2006-07-26 Argenta Discovery Ltd 2-Oxo-2H-Chromene Compounds
EP2492268A1 (en) 2006-07-22 2012-08-29 Oxagen Limited Compounds having CRTH2 antagonist activity
SG174069A1 (en) 2006-08-21 2011-09-29 Array Biopharma Inc 4-substituted phenoxyphenylacetic acid derivatives
AU2006352195A1 (en) 2006-12-21 2008-06-26 Argenta Discovery Limited CRTH2 antagonists
GB0625842D0 (en) 2006-12-22 2007-02-07 Argenta Discovery Ltd Indolizine derivatives
US20100137300A1 (en) 2007-03-21 2010-06-03 George Hynd Indolizine Acetic Acid Derivatives as CRTH2 Antagonists
ATE544751T1 (de) 2007-03-29 2012-02-15 Pulmagen Therapeutics Asthma Ltd Chinolinderivate als crth2-rezeptorliganden
CN102898380A (zh) 2007-06-21 2013-01-30 艾克提麦斯医药品有限公司 一种crth2 拮抗剂的胺盐
GB0722216D0 (en) * 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
US20110124683A1 (en) * 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
ATE502920T1 (de) * 2007-12-14 2011-04-15 Pulmagen Therapeutics Asthma Ltd Indole und ihre therapeutische verwendung
BRPI0821197A2 (pt) 2007-12-19 2015-06-16 Amgen Inc Composto, composição farmacêutica, uso de um composto, processo, e, intermediário.
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2250161B1 (en) * 2008-01-18 2013-10-16 Atopix Therapeutics Limited Compounds having crth2 antagonist activity
EP2265581A1 (en) 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
US8501959B2 (en) * 2008-06-24 2013-08-06 Panmira Pharmaceuticals, Llc Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
US20110312945A1 (en) * 2008-10-01 2011-12-22 James Jia Crth2 modulators
US8524748B2 (en) * 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
AU2010276404A1 (en) * 2009-07-20 2012-02-02 Vetegen, Llc A stable pharmaceutical omeprazole formulation for oral administration
JP2013501052A (ja) 2009-08-05 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２アンタゴニストおよびその用途
BR112012002353A2 (pt) * 2009-08-17 2018-03-13 The Penn State Res Foudation uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2
SG182398A1 (en) 2010-01-06 2012-08-30 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756270C2 (ru) * 2016-07-21 2021-09-29 Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. Производное индола, используемое в качестве ингибитора CRTH2

Also Published As

Publication number Publication date
CN104114169A (zh) 2014-10-22
KR20140113667A (ko) 2014-09-24
MX2014007239A (es) 2014-08-08
CA2859284A1 (en) 2013-06-20
US20140328861A1 (en) 2014-11-06
EA026456B1 (ru) 2017-04-28
WO2013088109A1 (en) 2013-06-20
JP2015500326A (ja) 2015-01-05
SG11201402796SA (en) 2014-06-27
BR112014014558A8 (pt) 2017-07-04
UA112667C2 (uk) 2016-10-10
NZ626990A (en) 2016-01-29
AU2012351342A1 (en) 2014-07-24
EP2790696A1 (en) 2014-10-22
BR112014014558A2 (pt) 2017-06-13
IL233131A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
EA201491008A1 (ru) Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
WO2013049770A3 (en) Methods of treating cancer
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
EA201490852A1 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
BR112013001122A2 (pt) composições ativas terapêuticas e seu método de uso
EP4389225A3 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
MD20130089A2 (ru) Метод лечения множественной миеломы
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
EA201490800A1 (ru) Способ ингибирования деубиквитинирующей активности
EA201490928A1 (ru) Способы лечения острых приступов подагры
MX394452B (es) Inhibicion de la actividad de olig2.
WO2014186623A3 (en) Methods and compositions for the treatment of a chagas disease
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
ZA201901367B (en) Inhibition of olig2 activity
WO2014201034A3 (en) Treatment for polyomavirus infection
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
EA201491870A1 (ru) Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента